168 related articles for article (PubMed ID: 30201983)
21. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
Toksvang LN; Grell K; Nersting J; Degn M; Nielsen SN; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Lepik K; Vaitkevičienė G; Griškevičius L; Quist-Paulsen P; Vora A; Moorman AV; Murdy D; Zimmermann M; Möricke A; Bostrom B; Joshi J; Hjalgrim LL; Dalhoff KP; Als-Nielsen B; Schmiegelow K
Leukemia; 2022 Jan; 36(1):33-41. PubMed ID: 34175901
[TBL] [Abstract][Full Text] [Related]
22. Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.
Matimba A; Li F; Livshits A; Cartwright CS; Scully S; Fridley BL; Jenkins G; Batzler A; Wang L; Weinshilboum R; Lennard L
Pharmacogenomics; 2014 Mar; 15(4):433-47. PubMed ID: 24624911
[TBL] [Abstract][Full Text] [Related]
23. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
Meyer JA; Carroll WL; Bhatla T
Expert Rev Hematol; 2013 Jun; 6(3):223-4. PubMed ID: 23782074
[No Abstract] [Full Text] [Related]
24. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
Lancaster DL; Patel N; Lennard L; Lilleyman JS
Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
[TBL] [Abstract][Full Text] [Related]
25. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
27. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
[TBL] [Abstract][Full Text] [Related]
28. Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
Hnízda A; Fábry M; Moriyama T; Pachl P; Kugler M; Brinsa V; Ascher DB; Carroll WL; Novák P; Žaliová M; Trka J; Řezáčová P; Yang JJ; Veverka V
Leukemia; 2018 Jun; 32(6):1393-1403. PubMed ID: 29535428
[TBL] [Abstract][Full Text] [Related]
29. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
[TBL] [Abstract][Full Text] [Related]
30. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia.
Chrzanowska M; Kolecki P; Duczmal-Cichocka B; Fiet J
Eur J Pharm Sci; 1999 Aug; 8(4):329-34. PubMed ID: 10425383
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
32. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
33. Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine-Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia.
Schwarz UI; Woldanski-Travaglini M; Swanston V; Mikhail M; Cacciotti C; Cairney E; Patel S; Seelisch J; Tole S; Wilejto M; Tirona RG; Kim RB; Zorzi AP
Clin Pharmacol Ther; 2023 Jun; 113(6):1326-1336. PubMed ID: 36932910
[TBL] [Abstract][Full Text] [Related]
34. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
[TBL] [Abstract][Full Text] [Related]
35. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
[TBL] [Abstract][Full Text] [Related]
36. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
Lennard L; Welch J; Lilleyman JS
Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
[TBL] [Abstract][Full Text] [Related]
37. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
[TBL] [Abstract][Full Text] [Related]
38. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
39. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
[TBL] [Abstract][Full Text] [Related]
40. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
Larsen RH; Utke Rank C; Grell K; Nørgaard Møller L; Malthe Overgaard U; Kampmann P; Nersting J; Degn M; Nygaard Nielsen S; Holst H; Klug Albertsen B; Skov Wehner P; Thude Callesen M; Kanerva J; Leth Frandsen T; Als-Nielsen B; Lyngsie Hjalgrim L; Schmiegelow K
Haematologica; 2021 Nov; 106(11):2824-2833. PubMed ID: 34047177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
